The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib

被引:0
|
作者
Omran, Mervat M. [1 ]
Ibrahim, Amel B. [2 ]
Abdelfattah, Raafat [3 ]
Moussa, Heba S. [4 ]
Shouman, Samia A. [1 ]
Hamza, Marwa S. [5 ]
机构
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词
Imatinib mesylate; CML; adherence; trough; peak; CHRONIC MYELOGENOUS LEUKEMIA; CYTOGENETIC RESPONSES; TYROSINE KINASE; BLAST CRISIS; THERAPY; NONADHERENCE; OUTCOMES;
D O I
10.1080/10428194.2024.2403671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
  • [41] VEGF in chronic myeloid leukemia treated with interferon and imatinib
    Aguayo, Alvaro
    LEUKEMIA RESEARCH, 2014, 38 (06) : 660 - 661
  • [42] Good adherence to imatinib therapy among patients with chronic myeloid leukemia—a single-center observational study
    Sofia Jönsson
    Bob Olsson
    Jenny Söderberg
    Hans Wadenvik
    Annals of Hematology, 2012, 91 : 679 - 685
  • [44] Chronic myeloid leukemia and its treatment with imatinib
    Treuil, Pascal
    ACTUALITES PHARMACEUTIQUES, 2008, 47 (473): : 25 - 30
  • [45] Treatment of chronic myeloid leukemia with imatinib mesylate
    Ohno R.
    International Journal of Clinical Oncology, 2006, 11 (3) : 176 - 183
  • [46] Imatinib mesylate and treatment of chronic myeloid leukemia
    Yamada, Hisashi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 39P - 39P
  • [47] Imatinib in the treatment of chronic myeloid leukemia in Morocco
    Dakkoune, Mariem
    Qachouh, Meryem
    Zoukal, Sofia
    Hassoune, Samira
    Khoubila, Nisrine
    Cherkaoui, Siham
    Lamchahab, Mouna
    Rachid, Mohamed
    Madani, Abdellah
    Quessar, Asmaa
    BULLETIN DU CANCER, 2020, 107 (09) : 861 - 866
  • [48] The Impact of Early Molecular Response in Event Free Survival in Patients with Chronic Myeloid Leukemia Treated with Imatinib
    Fogliatto, Laura
    Zanella Capra, Marcelo Eduardo
    Shaan, Mariza
    Costa, Tito Vanelli
    Torriani, Mayde Seadi
    Zanandrea Contin, Luis Carlos
    Breunig, Raquel
    Fassina, Katia
    Fernandes, Mario Sergio
    Almeida, Denise
    Schilling, Marco Antonio
    Hellwig, Tania
    Daltoe, Tiago
    Zardo, Adriana
    Moschen, Mariangela
    Nene, Moema
    Silveira, Juarez Fontoura
    Soares, Tahiane Brum
    Daudt, Liane Esteves
    Friedrisch, Joao
    Silla, Lucia
    BLOOD, 2014, 124 (21)
  • [49] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Albano, F.
    Abruzzese, E.
    Levato, L.
    Cavazzini, F.
    Lurlo, A.
    Stagno, F.
    Ferrero, D.
    Porretto, F.
    Martino, B.
    Rupoli, S.
    Intermesoli, T.
    Fava, C.
    Pierri, I.
    Palandri, F.
    Venturi, C.
    Soverini, S.
    Luatti, S.
    Alimena, G.
    Pane, F.
    Martinelli, G.
    Saglio, G.
    Cavo, M.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2013, 98 : 59 - 59
  • [50] Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy
    Proschmann, Rick
    Baldow, Christoph
    Rothe, Tino
    Suttorp, Meinolf
    Thiede, Christian
    Tauer, Josephine T.
    Mfiller, Martin C.
    Hochhaus, Andreas
    Roeder, Ingo
    Glauche, Ingmar
    HAEMATOLOGICA, 2017, 102 (02) : E39 - E42